Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Panobinostat (formerly known as LBH-589 and NVP LBH-589; trade name Farydak) is a novel, potent and broad-spectrum/non-selective/pan-HDAC inhibitor with potential anticancer activity. It inhibits HDAC in a cell-free assay with an IC50 of 5 nM. It also induces strong cell growth inhibition, cell-cycle arrest, and apoptosis in a time- and dose-dependent manner in both Philadelphia chromosome-negative (Ph-) activate lymphoblastic leukemia (ALL) cell lines. These effects are associated with the induction of histone (H3K9 and H4K8) hyperacetylation, activation of p21 and p27, and suppression of c-Myc. It not only induces apoptosis in multiple myeloma cells through caspase activation and poly(ADP-ribose) polymerase (PARP) cleavage. The FDA approved panobinostat in February 2015 for the treatment of multiple myeloma patients who had undergone at least two prior treatments, such as bortezomib and an immunomodulatory drug.
Targets |
HDAC; HIV-1
|
|
---|---|---|
ln Vitro |
|
|
ln Vivo |
|
|
Enzyme Assay |
Panobinostat is a non-selective histone deacetylase (HDAC) inhibitor.
|
|
Cell Assay |
The annexin V-FITC apoptosis detection kit is used to stain both untreated and LBH589-treated human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells) cells. Me. Flow cytometry is used to calculate the percentage of nonviable and apoptotic cells. Using a CyAn ADP Violet cytometer, a minimum of 5 × 104 cells are obtained. The percentages of apoptosis and cell viability are determined by adding together all annexin V-positive, PI-positive, and annexin V/PI-positive cells.Furthermore, percentages of cell viability are calculated by adding together all annexin V-positive, PI-positive, and annexin V/PI-positive cells.
|
|
Animal Protocol |
|
|
References |
Molecular Formula |
C21H23N3O2
|
---|---|
Molecular Weight |
349.43
|
Exact Mass |
349.18
|
Elemental Analysis |
C, 72.18; H, 6.63; N, 12.03; O, 9.16
|
CAS # |
404950-80-7
|
Related CAS # |
404950-80-7;960055-56-5 (lactate); 960055-60-1 (mesylate);960055-50-9 (acetate); 960055-54-3 (fumarate); 960055-57-6
|
Appearance |
White to off-white solid powder
|
SMILES |
CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO
|
InChi Key |
FPOHNWQLNRZRFC-ZHACJKMWSA-N
|
InChi Code |
InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+
|
Chemical Name |
(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide
|
Synonyms |
NVP-LBH589; NVP-LBH 589; LBH589; LBH 589; LBH-589; Panobinostat; Brand name Farydak
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.8618 mL | 14.3090 mL | 28.6180 mL | |
5 mM | 0.5724 mL | 2.8618 mL | 5.7236 mL | |
10 mM | 0.2862 mL | 1.4309 mL | 2.8618 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04341311 | Active Recruiting |
Drug: Panobinostat Drug: Marizomib |
Pediatric Cancer Diffuse Glioma |
Dana-Farber Cancer Institute | August 10, 2020 | Phase 1 |
NCT02717455 | Active Recruiting |
Drug: LBH589 | Glioma | Pediatric Brain Tumor Consortium | June 28, 2016 | Phase 1 |
NCT02471430 | Active Recruiting |
Drug: Pegylated Interferon-alpha2a Drug: Panobinostat |
HIV Infection | Massachusetts General Hospital | May 2016 | Phase 1 Phase 2 |
NCT02506959 | Active Recruiting |
Drug: Panobinostat Drug: Melphalan |
Plasma Cell Leukemia Plasmacytoma |
M.D. Anderson Cancer Center | September 14, 2015 | Phase 2 |
NCT02386800 | Recruiting | Drug: panobinostat Drug: ruxolitinib |
Thalassemia Polycythemia Vera |
Novartis Pharmaceuticals | March 5, 2015 | Phase 4 |
Action of LBH589 on acetylation of histone H4 in myeloma cells and on the proliferation of multiple myeloma cells. Cancer Res . 2006 Jun 1;66(11):5781-9. td> |
LBH589 causes death of patient cells with multiple myeloma and potentiates the antimyeloma action of bortezomib, dexamethasone, and melphalan. Cancer Res . 2006 Jun 1;66(11):5781-9. td> |
Efficacy of the in vitro combinations of panobinostat with other anti-myeloma agents in MM. Haematologica . 2010 May;95(5):794-803. td> |
Efficacy of single-agent panobinostat in xenograft models of MM. Haematologica . 2010 May;95(5):794-803. td> |
LBH589 inhibits proliferation of MOLT-4 and Reh cells. Blood . 2008 May 15;111(10):5093-100. td> |
LBH589 blocks cell-cycle progression of MOLT-4 and Reh cells. Blood . 2008 May 15;111(10):5093-100. td> |
LBH589 induces hyperacetylation of histones H3K9 and H4K8, and modulates expression of cell-cycle control genes. Blood . 2008 May 15;111(10):5093-100. td> |